acute myeloid leukemia

Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults

By MedXY 09/18/2026

A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan regimens in selected cases.

$Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL$

Hematology-Oncology news

Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL

By MedXY 09/18/2026

A phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.

Hematology-Oncology news Oncology

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry

By MedXY 09/16/2026

In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acute GvHD incidence.

Hematology-Oncology news

Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy

By MedXY 09/13/2026

PRMT9-mediated arginine methylation drives venetoclax resistance in AML by altering RNA splicing and protein synthesis. Targeting PRMT9 restores venetoclax sensitivity, offering a promising approach to combat resistant AML.

Hematology-Oncology news

Impact of Induction Course Number on Outcomes of Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide in AML

By MedXY 09/12/2026

This study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse with two inductions.

Hematology-Oncology news

Comparative Effectiveness of Azacitidine and Decitabine in TP53-Mutant Acute Myeloid Leukemia: Insights from the COMMAND Registry

By MedXY 09/12/2026

This study analyzes outcomes of azacitidine versus decitabine, with or without venetoclax, in TP53-mutant AML, revealing comparable survival outcomes and highlighting the independent prognostic impact of multi-hit TP53 status.

Hematology-Oncology news Oncology

TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

By MedXY 09/10/2026

TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.

Hematology-Oncology news

Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation

By MedXY 09/10/2026

The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratification.

Hematology-Oncology news

Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE Trial

By MedXY 09/09/2026

The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy.

Hematology-Oncology news

Unveiling the Role of snoRNA-Derived RNAs in Hematopoiesis and Acute Myeloid Leukemia Prognosis

By MedXY 09/09/2026

This article explores the expression and functional impact of snoRNA-derived RNAs in healthy blood formation and acute myeloid leukemia, highlighting their potential as biomarkers and therapeutic targets.

Hematology-Oncology news Oncology

Targeting Acute Myeloid Leukemia through Multi-Functional Small Molecules: Insights from Cheminformatics and Mitochondrial Modulation

By MedXY 09/01/2026

Cheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlighting a promising avenue for targeted AML treatment.

Hematology-Oncology news

Decoding Chromosome 5q Deletion: Driving Aneuploidy Evolution and Therapeutic Strategies in Complex Karyotype Myeloid Neoplasms

By MedXY 09/01/2026

Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.

Hematology-Oncology news Pathology & Lab Medicine

Enhancing Prognostic Accuracy in Acute Myeloid Leukemia through DNA Methylation Signatures

By MedXY 08/28/2026

DNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.

Hematology-Oncology news

Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies

By MedXY 08/25/2026

This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved survival metrics with treosulfan.

Hematology-Oncology news Oncology

Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication

By MedXY 08/25/2026

This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.

$Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights$

Hematology-Oncology news Oncology

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights

By MedXY 08/24/2026

A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostication.

Hematology-Oncology news

Transcription Factor NFE2: A Crucial Regulator of Redox Balance and Chemotherapy Resistance in Acute Myeloid Leukemia

By MedXY 08/24/2026

NFE2 drives leukemic transformation through redox regulation, modulating glutathione homeostasis and detoxification pathways, and confers chemotherapy resistance in AML. Targeting NFE2 may enhance therapeutic efficacy and improve patient outcomes.

Hematology-Oncology news

Engineering High-Avidity Cathepsin-G-Specific CAR T Cells: A Promising Therapeutic Strategy for Acute Myeloid Leukemia

By MedXY 08/23/2026

This article reviews the development of high-avidity cathepsin-G-specific CAR T cells engineered with enhanced functional features to selectively target acute myeloid leukemia without hematopoietic toxicity, highlighting their preclinical efficacy, mechanistic insights, and clinical potential.

Hematology-Oncology news Oncology

Relapse and Survival Benchmarks in Non-Transplanted AML Patients Achieving First Complete Remission

By MedXY 08/17/2026

A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in reducing relapse.

Hematology-Oncology news

Unraveling the Blockade: How Mutant IDH1 Impairs Neutrophil Differentiation in Preleukemic Hematopoiesis

By MedXY 08/17/2026

Mutant IDH1 in acute myeloid leukemia causes a reversible block in neutrophil differentiation by repressing myeloid progenitor transcriptional programs, highlighting a preleukemic defect with therapeutic implications.